41
Participants
Start Date
June 30, 2010
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
sorafenib with everolimus
"Treatment will be with sorafenib 400 mg orally twice a day and everolimus 5 mg orally daily. Restage every 2 cycles \*Cycle = 4 weeks of treatment.~Subjects may consent to allowing blood to be drawn for DNA. Two blue top tubes will be required. Approximately 5-6 ml will be needed. This may be done at anytime, including before, during, or after treatment. This is not required to participate in the study."
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Westchester, Harrison
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack
Memorial Sloan Kettering Cancer Center, Basking Ridge
Memorial Sloan Kettering Cancer Center
OTHER